Stoke Therapeutics Files 8-K, Confirms Nasdaq Listing

Ticker: STOK · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1623526

Stoke Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyStoke Therapeutics, Inc. (STOK)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, exchange-listing

TL;DR

**Stoke Therapeutics filed a routine 8-K, confirming its Nasdaq listing and regulatory compliance.**

AI Summary

Stoke Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on the Nasdaq Global Select Market under the ticker STOK. This filing, while routine, confirms the company's continued compliance with SEC regulations and its listing status, which is important for investors as it ensures transparency and liquidity for their shares.

Why It Matters

This filing confirms Stoke Therapeutics' ongoing compliance with SEC reporting requirements and its active listing on the Nasdaq, which is fundamental for investor confidence and market access.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not contain any information that would significantly alter the company's risk profile.

Analyst Insight

This is a routine administrative filing that provides no new material information to warrant an immediate investment action. Investors should continue to monitor for more substantive filings regarding financial performance or operational developments.

Key Numbers

  • 001-38938 — Commission File Number (identifies Stoke Therapeutics' registration with the SEC)
  • 47-1144582 — IRS Employer Identification No. (identifies Stoke Therapeutics for tax purposes)
  • 781-430-8200 — Registrant's Telephone Number (contact information for Stoke Therapeutics)
  • $0.0001 — Par Value per Share (the nominal value assigned to each share of common stock)

Key Players & Entities

  • Stoke Therapeutics, Inc. (company) — the registrant filing the 8-K
  • Nasdaq Global Select Market (company) — the exchange where Stoke Therapeutics' common stock is registered
  • STOK (other) — the trading symbol for Stoke Therapeutics' common stock
  • January 8, 2024 (date) — the date of the earliest event reported in the 8-K
  • $0.0001 (dollar_amount) — par value per share of common stock

Forward-Looking Statements

  • Stoke Therapeutics will continue to maintain its listing on the Nasdaq Global Select Market. (Stoke Therapeutics, Inc.) — high confidence, target: 2025-01-08
  • The company will continue to file routine SEC disclosures as required. (Stoke Therapeutics, Inc.) — high confidence, target: 2025-01-08

FAQ

What is the primary purpose of this 8-K filing by Stoke Therapeutics, Inc.?

The primary purpose of this 8-K filing, dated January 8, 2024, is to disclose general corporate information, including its status as a registrant under the Securities Exchange Act of 1934, and to confirm its common stock is registered on the Nasdaq Global Select Market under the trading symbol STOK.

On which stock exchange is Stoke Therapeutics, Inc.'s common stock registered?

Stoke Therapeutics, Inc.'s common stock, with a par value of $0.0001 per share, is registered on the Nasdaq Global Select Market under the trading symbol STOK, as stated in the filing.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 8, 2024, as explicitly stated in the document.

What is the business address and phone number of Stoke Therapeutics, Inc. as listed in the filing?

According to the filing, Stoke Therapeutics, Inc.'s business address is 45 Wiggins Ave, Bedford, Massachusetts, 01730, and its telephone number is (781) 430-8200.

Does this 8-K filing indicate that Stoke Therapeutics, Inc. is an emerging growth company?

The filing includes a checkbox section to indicate if the registrant is an emerging growth company, but the box is not checked, implying the company does not identify as an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Filing Stats: 1,126 words · 5 min read · ~4 pages · Grade level 15.5 · Accepted 2024-01-08 08:09:56

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo

Filing Documents

01

Item 7.01 Regulation FD. On January 8, 2024, Stoke Therapeutics, Inc., a Delaware corporation (the "Company"), posted an updated corporate presentation with additional information to its website, in advance of making a formal presentation of such information (the "Presentation") at the J.P. Morgan Healthcare Conference on January 10, 2024. The Company is furnishing a copy of the Presentation, a full copy of which is attached hereto as Exhibit 99.1. The information furnished with this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

01

Item 8.01 Other Events. Additionally, on January 8, 2024, the Company announced updated anticipated timing of certain milestones, including the following: STK-001: Dravet Syndrome In the first quarter of 2024, the Company plans to report additional clinical and modeling data from 81 patients treated in the Phase 1/2a studies of STK-001 (MONARCH and ADMIRAL) and the two ongoing open-label extension studies (OLE) (SWALLOWTAIL and LONGWING), including: Safety, pharmacokinetic modeling, and cerebrospinal fluid results; Seizure frequency data from approximately 20 patients who received 1, 2, or 3 initial doses of 70mg of STK-001 and were followed for six months; The effects of repeat doses of STK-001 (30mg, 45mg) on seizure frequency and cognition and behavior from patients treated in the SWALLOWTAIL and LONGWING OLE studies. Pending the results of the Q1 data readout, the Company plans to proceed with Phase 3 preparation activities, including discussions with global regulatory agencies, availability of chronic toxicology data, preparation of the investigator brochure, submission of a final protocol to regulatory agencies and institutional review boards. STK-002: Autosomal Dominant Optic Atrophy Phase 1 study (OSPREY) of STK-002 is expected to start in the UK in 2024.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Presentation, dated as of January 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to the ability of STK-001 to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior or cognition at the indicated dosing levels or at all; the timing and expected progress of clinical trials, data readouts and presentations for STK-001 and STK-002; the timing of regulatory interactions or the outcome thereof; and the Company's cash runway. Statements including words such as "anticipate," "plan," "will," "continue," "expect," or "ongoing" and statements in the future tense are forward- looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause our results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company's ability to advance, obtain regulatory approval of, and ultimately commercialize its product candidates; the timing of data readouts and interim and final results of preclinical and clinical trials; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; preliminary interim data readouts of ongoing trials may show results that change when such trials are completed; the Company's ability to fund development activities and achieve development goals into 2025; the Company's ability to protect its intellectual property; the direct or indirect impact of global business, political and macroeconomic conditions, including inflation, interest rate volatility, cybersecu

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STOKE THERAPEUTICS, INC. Date: January 8, 2024 By: /s/ Stephen J. Tulipano Stephen J. Tulipano Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.